205 related articles for article (PubMed ID: 31500870)
21. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
[TBL] [Abstract][Full Text] [Related]
22. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant chemoradiotherapy in advanced gastric cancer: experience in 168 patients].
Isa O N; Russo N M; López V H
Rev Med Chil; 2014 Feb; 142(2):199-203. PubMed ID: 24953108
[TBL] [Abstract][Full Text] [Related]
27. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency.
Polom K; Böger C; Smyth E; Marrelli D; Behrens HM; Marano L; Becker T; Lordick F; Röcken C; Roviello F
Eur J Surg Oncol; 2018 May; 44(5):626-631. PubMed ID: 29545085
[TBL] [Abstract][Full Text] [Related]
28. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
29. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.
Hong YS; Kim SY; Lee JS; Nam BH; Kim KP; Kim JE; Park YS; Park JO; Baek JY; Kim TY; Lee KW; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
J Clin Oncol; 2019 Nov; 37(33):3111-3123. PubMed ID: 31593484
[TBL] [Abstract][Full Text] [Related]
31. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Kim S; Lim DH; Lee J; Kang WK; MacDonald JS; Park CH; Park SH; Lee SH; Kim K; Park JO; Kim WS; Jung CW; Park YS; Im YH; Sohn TS; Noh JH; Heo JS; Kim YI; Park CK; Park K
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1279-85. PubMed ID: 16099596
[TBL] [Abstract][Full Text] [Related]
32. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods.
Kim DH; Kim SM; Hyun JK; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Jul; 20(7):2317-27. PubMed ID: 23677605
[TBL] [Abstract][Full Text] [Related]
33. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
35. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
36. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
Cao Y; Liu H; Li H; Lin C; Li R; Wu S; Zhang H; He H; Zhang W; Xu J
JAMA Surg; 2017 Nov; 152(11):e173120. PubMed ID: 28903131
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
38. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Arpaci E; Bilici M; Uncu D; Cetin B; Dane F; Inane M; Kaplan MA; Cayir K; Yetisyigit T; Ozdemir N; Inal A; Aksoy S; Alkis N; Tekin SB; Eroglu C; Turhal S; Benekli M; Buyukberber S
Hepatogastroenterology; 2012 Oct; 59(119):2343-7. PubMed ID: 22389301
[TBL] [Abstract][Full Text] [Related]
40. Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer.
Araki I; Washio M; Yamashita K; Hosoda K; Ema A; Mieno H; Moriya H; Katada N; Kikuchi S; Watanabe M
Surg Today; 2018 May; 48(5):478-485. PubMed ID: 29256147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
